Glenmark Pharmaceuticals Limited announced that the Company has on 15 January 2021 redeemed USD 10,000,000 in aggregate principal amount of its 2021 Notes, representing approximately 5.00% of the aggregate principal amount of the 2021 Notes at the time of initial listing. As on the date of this announcement, no amount is outstanding in connection with the 2021 Notes.